JP2010529128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529128A5 JP2010529128A5 JP2010511198A JP2010511198A JP2010529128A5 JP 2010529128 A5 JP2010529128 A5 JP 2010529128A5 JP 2010511198 A JP2010511198 A JP 2010511198A JP 2010511198 A JP2010511198 A JP 2010511198A JP 2010529128 A5 JP2010529128 A5 JP 2010529128A5
- Authority
- JP
- Japan
- Prior art keywords
- igf
- igf1
- composition
- pro
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 18
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 16
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 15
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 15
- 230000001225 therapeutic effect Effects 0.000 claims 11
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 claims 3
- 108010079413 glycyl-prolyl-glutamic acid Proteins 0.000 claims 3
- 102100033367 Appetite-regulating hormone Human genes 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- -1 optionally Proteins 0.000 claims 2
- 210000000225 synapse Anatomy 0.000 claims 2
- 230000027912 synapse maturation Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 claims 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 1
- 101710103504 CXXC-type zinc finger protein 1 Proteins 0.000 claims 1
- 102100036168 CXXC-type zinc finger protein 1 Human genes 0.000 claims 1
- 150000008574 D-amino acids Chemical group 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims 1
- QLROSWPKSBORFJ-BQBZGAKWSA-N L-Prolyl-L-glutamic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 QLROSWPKSBORFJ-BQBZGAKWSA-N 0.000 claims 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims 1
- 229940084576 Neurotransmitter agonist Drugs 0.000 claims 1
- 229940123247 Neurotransmitter antagonist Drugs 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 101710142969 Somatoliberin Proteins 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 claims 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 claims 1
- 108010077515 glycylproline Proteins 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 239000003324 growth hormone secretagogue Substances 0.000 claims 1
- 102000044162 human IGF1 Human genes 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000007996 neuronal plasticity Effects 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 108010070643 prolylglutamic acid Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000000580 secretagogue effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000003977 synaptic function Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93373807P | 2007-06-08 | 2007-06-08 | |
| PCT/US2008/007107 WO2008153929A1 (en) | 2007-06-08 | 2008-06-06 | Igf for the treatment of rett syndrome and synaptic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010529128A JP2010529128A (ja) | 2010-08-26 |
| JP2010529128A5 true JP2010529128A5 (enExample) | 2011-07-21 |
Family
ID=39891784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010511198A Pending JP2010529128A (ja) | 2007-06-08 | 2008-06-06 | レット症候群および他の障害の処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7994127B2 (enExample) |
| EP (1) | EP2164509A1 (enExample) |
| JP (1) | JP2010529128A (enExample) |
| CN (1) | CN101820896A (enExample) |
| AU (1) | AU2008262387A1 (enExample) |
| BR (1) | BRPI0812768A2 (enExample) |
| CA (1) | CA2689549A1 (enExample) |
| WO (1) | WO2008153929A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| MX373000B (es) | 2005-09-14 | 2020-05-21 | Mannkind Corp | Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas. |
| US8969295B2 (en) * | 2006-04-14 | 2015-03-03 | Massachusetts Institute Of Technology | Identifying and modulating molecular pathways that mediate nervous system plasticity |
| TWI494123B (zh) | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
| CN102348798A (zh) | 2009-01-16 | 2012-02-08 | 麻省理工学院 | 孤独症谱系障碍的诊断和治疗 |
| EP2571515B1 (en) | 2010-05-17 | 2016-11-30 | Icahn School of Medicine at Mount Sinai | Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression |
| LT2667715T (lt) * | 2011-01-27 | 2017-11-10 | Neuren Pharmaceuticals Limited | Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį |
| MX353285B (es) * | 2011-04-01 | 2018-01-05 | Mannkind Corp | Paquete de blister para cartuchos farmaceuticos. |
| DK2734634T3 (da) * | 2011-07-22 | 2019-10-21 | Univ Chicago | Igf-1 til anvendelse til behandling af migræne |
| HK1201475A1 (en) | 2011-10-24 | 2015-09-04 | Mannkind Corporation | Methods and compositions for treating pain |
| WO2014085480A1 (en) * | 2012-11-28 | 2014-06-05 | Neuren Pharmaceuticals Limited | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid |
| ES2495266B8 (es) * | 2013-02-13 | 2015-11-12 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| RU2017110868A (ru) | 2014-09-25 | 2018-10-25 | Колд Спринг Харбор Лаборатори | Лечение синдрома ретта |
| JP6866379B2 (ja) | 2016-01-26 | 2021-04-28 | アナベックス ライフ サイエンシズ コーポレイション | 神経発達障害療法 |
| TWI601821B (zh) * | 2016-04-15 | 2017-10-11 | 中央研究院 | 治療神經發展性疾病 |
| WO2018217766A1 (en) | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
| CN108187031A (zh) * | 2018-02-11 | 2018-06-22 | 中国人民解放军第四军医大学 | rhIGF1在制备治疗脆性X综合征药物中的应用 |
| JP2022524927A (ja) | 2019-02-02 | 2022-05-11 | ステモニックス インコーポレイティド | 創薬のためのヒトスフェロイドの使用方法 |
| JP2022547948A (ja) | 2019-09-09 | 2022-11-16 | ザ・ユニバーシティ・オブ・シカゴ | 片頭痛の処置のための併用療法 |
| WO2021100614A1 (ja) * | 2019-11-19 | 2021-05-27 | 国立大学法人京都大学 | 大豆ペプチド及び／又はコラーゲンペプチド含有神経心理学的機能改善剤 |
| WO2022055045A1 (ko) * | 2020-09-08 | 2022-03-17 | 주식회사 선마린바이오테크 | 콜라게나제 저해 활성 펩타이드 유도체 및 이의 용도 |
| US20240148835A1 (en) * | 2021-01-28 | 2024-05-09 | University Of Florida Research Foundation, Incorporated | Treating disorders associated with dyrk1a dysfunction |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| IL71991A (en) | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
| AU637316B2 (en) | 1988-01-28 | 1993-05-27 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
| AU628322B2 (en) | 1988-01-28 | 1992-09-17 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
| SE8803847A0 (sv) | 1988-10-27 | 1990-04-28 | Kabigen Ab | Neuromodulerande peptid |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| ES2101865T3 (es) | 1991-08-01 | 1997-07-16 | Genentech Inc | Igf-1 para mejorar el estado neural. |
| US5861373A (en) * | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
| US5420112A (en) | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
| US5446024A (en) | 1993-12-17 | 1995-08-29 | Genentech, Inc. | Purification of insulin-like growth factor |
| CA2178711A1 (en) | 1993-12-23 | 1995-06-29 | Peter David Gluckman | Composition and methods to improve neural outcome |
| US5565428A (en) | 1995-05-22 | 1996-10-15 | Genentech, Inc. | Method of administration of IGF-I |
| US20020132252A1 (en) | 1997-06-16 | 2002-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
| US7304029B1 (en) | 1998-09-03 | 2007-12-04 | Neuren Pharmaceuticals Ltd. | Neuroprotective effect of growth hormone |
| AU762351B2 (en) | 1999-01-06 | 2003-06-26 | Genentech Inc. | Insulin-like growth factor (IGF) I mutant variants |
| WO2002016408A2 (en) | 2000-08-24 | 2002-02-28 | Neuronz Ltd. | Gpe analogs |
| WO2002057241A1 (en) | 2000-12-22 | 2002-07-25 | Bayer Pharmaceuticals Corporation | 8-(AMINOALKOXYMINO)-8H-DIBENZO[a,e]TRIAZOLO[4,5-c]CYCLOHEPTENES AS GROWTH HORMONE SECRETAGOGUES |
| WO2002056873A2 (en) | 2000-12-22 | 2002-07-25 | Bayer Pharmaceuticals Corporation | 2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues |
| DE60217066T4 (de) | 2001-02-09 | 2010-07-01 | Genentech, Inc., South San Francisco | Kristallisierung von igf-1 |
| US7863304B2 (en) | 2001-05-24 | 2011-01-04 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
| EP1401808B1 (en) | 2001-05-24 | 2009-07-08 | Neuren Pharmaceuticals Limited | Gpe analogs and peptidomimetics |
| US7485630B2 (en) | 2003-03-20 | 2009-02-03 | Neuren Pharmaceuticals Limited | Neuroprotective macrocyclic compounds and methods for their use |
| US20050027110A1 (en) | 2003-07-24 | 2005-02-03 | Michael Russell | Drug delivery in the nervous system |
| DK2274978T3 (en) | 2003-09-12 | 2015-06-15 | Ipsen Biopharmaceuticals Inc | Methods of treating an insulin-like growth factor-I (IGF-I) deficiency |
| US20070224165A1 (en) | 2003-10-23 | 2007-09-27 | Neuren Pharmaceuticals Limited | Neuroprotective Effects of Gly-Pro-Glu Following Intravenous Infusion |
| US20060104969A1 (en) * | 2004-08-16 | 2006-05-18 | Massachusetts Institute Of Technology | Compositions and methods for enhancing structural and functional nervous system reorganization and recovery |
| JP2008511838A (ja) | 2004-08-30 | 2008-04-17 | テルシカ・インク | インシュリン様成長因子欠乏疾患の診断及び治療のための方法及び装置 |
| KR20060040550A (ko) | 2004-11-05 | 2006-05-10 | 마루이시세이야쿠가부시키가이샤 | 인슐린유사 성장인자-1 분비촉진제 |
| US8158582B2 (en) | 2005-06-02 | 2012-04-17 | Tercica, Inc. | Methods for treatment of insulin-like growth factor-1 deficiency |
| US8969295B2 (en) * | 2006-04-14 | 2015-03-03 | Massachusetts Institute Of Technology | Identifying and modulating molecular pathways that mediate nervous system plasticity |
-
2008
- 2008-06-06 BR BRPI0812768-9A2A patent/BRPI0812768A2/pt not_active IP Right Cessation
- 2008-06-06 AU AU2008262387A patent/AU2008262387A1/en not_active Abandoned
- 2008-06-06 US US12/134,707 patent/US7994127B2/en active Active
- 2008-06-06 CA CA002689549A patent/CA2689549A1/en not_active Abandoned
- 2008-06-06 EP EP08768183A patent/EP2164509A1/en not_active Withdrawn
- 2008-06-06 WO PCT/US2008/007107 patent/WO2008153929A1/en not_active Ceased
- 2008-06-06 JP JP2010511198A patent/JP2010529128A/ja active Pending
- 2008-06-06 CN CN200880024937A patent/CN101820896A/zh active Pending
-
2011
- 2011-08-08 US US13/204,817 patent/US20120177630A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2954475C (en) | Apoe mimetic peptides and higher potency to clear plasma cholesterol | |
| CN102292346B (zh) | 肥胖的治疗 | |
| WO2024086381A2 (en) | Methods of stimulating appetite and/or increasing body weight using non-naturally occurring melanocortin receptor antagonist analogs | |
| US7579319B2 (en) | Methods for improving the structure and function of arterioles | |
| JPH07508025A (ja) | インスリン様増殖因子（ｉｇｆ−１）類似体 | |
| HUP0101411A2 (hu) | 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása | |
| JP2008500373A5 (enExample) | ||
| JP2019089834A5 (enExample) | ||
| AU2017203911B2 (en) | Apolipoprotein mimetics and uses thereof | |
| JPWO2021100614A5 (enExample) | ||
| Collins et al. | Trofinetide. Glycine-proline-glutamate (GPE) analogue, treatment of Rett syndrome, treatment of fragile X syndrome | |
| JP2020511425A5 (enExample) | ||
| JP2008501632A5 (enExample) | ||
| EP2408809B1 (fr) | Peptides modulant l'activite de l'igf-1 et leurs applications | |
| JP2021514961A (ja) | 神経変性または神経炎症の治療または予防のための新規のｉｌ−４−／ｉｌ−１３−由来ペプチド化合物 | |
| TWI275398B (en) | New therapeutic uses of tri-, tetra-, penta-,and polypeptides | |
| Battey et al. | Bombesin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database | |
| EP1602931A1 (en) | SR-A antagonists | |
| Reeve Jr et al. | Synthesis of biologically active canine CCK-58 | |
| JP2023544910A (ja) | コロナウイルス治療法 | |
| CN100341566C (zh) | 芋螺多肽衍生物用于制备戒毒药物的用途 | |
| AU2002228260B2 (en) | Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients | |
| JP2009520772A5 (enExample) | ||
| Ge et al. | Research Progress on Neuroprotection of In-sulin-Like Growth Factor-1 towards Glutamate-Induced Neurotoxicity. Cells 2022, 11, 666 | |
| Prakash et al. | Molecular dynamics Simulations of C-terminal decapeptide of gastrin-releasing peptide in DMPC bilayers: Structure, stability and orientation of the peptide hormone within the bilayers |